SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agenus (AGEN) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (79)7/10/2006 9:23:17 AM
From: rkrw  Read Replies (1) | Respond to of 146
 
Royalties should be low, maybe 1%?

Patent expires in 08. Any idea why gsk would pay royalties at all? Something difficult about the supply?
Adjuvant being applied to about 20 gsk vaccines in development, first commercial sale expected in 2010.



To: scaram(o)uche who wrote (79)7/11/2006 6:38:10 PM
From: scaram(o)uche  Read Replies (2) | Respond to of 146
 
I said It's really, really old.

Good ol' Honest Garo, in a conference call to mark the momentous event, said "QS-21 is a revolutionary new adjuvant".

There ain't no meeting in the middle. It's old.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News